Product
Supplier
Encyclopedia
Inquiry

EN

Home > Biochemical Engineering > Polypeptide > Bivalirudin List

Bivalirudin List

:47 products from 46 suppliers

Company Type
Supplier Location

All

Zhejiang(10)

Jiangsu(3)

Shanghai(3)

Sichuan(2)

Anhui(1)

Beijing(1)

Guangdong(1)

Hubei(1)

Shandong(1)

Tianjin(1)

+ View More - View Less
Grade
+ View More - View Less
Content
+ View More - View Less

Bivalirudin 

Properties

Bivalirudin 

SDS

Bivalirudin

  • Price:

    $100/G FOB

  • CAS No.:

    128270-60-0

  • Grade:

    Pharmacy Grade

  • Content:

    99%

  • Packaging:

    0.001kg/as customer's requirment

Distributor  |  China
Main Products:

API,Intermediate

Bivalirudin Trifluoroacetate

  • Price:

    $1/G EXW

  • CAS No.:

    128270-60-0

  • Grade:

    Research and Industrial Grade

  • Content:

    98.00%

  • Packaging:

    Plastic bottles

Manufactory  |  China
Main Products:

Pharmaceutical Peptide,Cosmetic peptide,Custom peptides,API polypeptide,Amino acids and derivatives

Bivalirudin Trifluoroacetate CAS NO.128270-60-0

  • CAS No.:

    128270-60-0

  • Grade:

    Research grade

  • Packaging:

    0.001kg/Bottle

Manufactory  |  China
Main Products:

Pharmaceutical Peptide,Cosmetic peptide,Custom peptides,API polypeptide,Amino acids and derivatives

Bivalirudin, 128270-60-0

  • Price:

    $500-600/G FOB

  • CAS No.:

    128270-60-0

  • Grade:

    Chemical Grade

  • Content:

    98%

  • Packaging:

    1g/vial

Manufactory  |  China
Main Products:

peptide,Thymosin β4,Sermorelin,Caerulein,BPC-157

Bivalirudin Industrial Grade

  • CAS No.:

    128270-60-0

  • Grade:

    Industrial Grade

  • Packaging:

    0.01kg/0.10kg Bottle

Manufactory  |  China
Main Products:

Active Pharmaceutical Ingredient

Bivalirudin Trifluoroacetate 98%

  • CAS No.:

    128270-60-0

  • Grade:

    Chemical grade

  • Content:

    98%

  • Packaging:

    1kg/20kg Red Iron Drum

Manufactory  |  China
Main Products:

apis

Bivalirudin

Bivalirudin

  • CAS No.:

    128270-60-0

  • Content:

    99%

  • Packaging:

    25kg/drum;200kg/drum

Other  |  China
Bivalirudin

Bivalirudin

  • CAS No.:

    128270-60-0

  • Content:

    99%

Bivalirudin

Bivalirudin

  • CAS No.:

    128270-60-0

Bivalirudin

Bivalirudin

  • CAS No.:

    128270-60-0

Trading Company  |  Singapore
Description

Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.IC50 Value:Target: thrombinin vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) [1]. In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l [2]. Bivalirudin-facilitated binding of MPO

Usage

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis).Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials. Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.

View More View Less
Suggestions
Email:
Message:
Send Message